Reports

Drug name	NICE TAs	Comments
Sacubitril/Valsartan (Entresto®)	TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Amber Specialist initiation and stabilisation for adults
SACUBITRIL/VALSARTAN (ENTRESTO®)	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	Paediatrics
Sapropterin dihydrochloride (Kuvan)	TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
Sarilumab	TA485 - Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab	TA350 - Secukinumab for treating moderate to severe plaque psoriasis TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa
Selpercatinib (Retsevmo®)	TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small cell lung cancer TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer NICE TA 1038 Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over NICE TA 1039 Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over NICE TA 1042 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
Semaglutide (Wegovy®)	TA875 - Semaglutide for managing overweight and obesity	The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet.
Siponimod (Mayzent®)	TA656 - Siponimod for treating secondary progressive multiple sclerosis
Sirolimus solution	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant
Sirolimus solution#amber	TA85 - Immunosuppressive therapy for renal transplantation in adults	Post-transplant pre 2015

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports